Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Merck & company, inc. crawled time : 12:00 save search
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: 0.24%
H: 0.08%
C: -2.42%
mk-1084 keytruda lung merck cancer cell treatment trial
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Published: 2024-04-01 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: -0.23%
H: 0.19%
C: -0.52%
sales conference merck
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: -0.13%
H: 0.4%
C: -0.06%
ylynk-006 keytruda lung merck update cancer cell trial plus
Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease
Published: 2023-10-17 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: -0.13%
H: 0.47%
C: 0.16%
prevymis disease chmp kidney merck positive infection risk
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
Published: 2023-10-16 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: 0.18%
H: 1.12%
C: -0.06%
keytruda lung cancer cell treatment risk
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-10-10 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: -0.17%
H: 0.13%
C: -0.68%
ynote-671 lung merck cancer cell trial
Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
Published: 2023-09-28 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: 0.61%
H: 0.38%
C: -0.26%
fda license merck review treat hypertension application
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Published: 2023-09-22 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: -0.82%
LLY | News | $733.3 -1.66% 1.4M
|
Health Technology
|
| O: -2.93%
H: 1.22%
C: 0.32%
keytruda lung merck update cancer cell trials plus
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Published: 2023-09-20 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: 0.79%
H: 0.18%
C: -0.83%
keytruda fda review cancer treatment application grants plus
FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Published: 2023-09-19 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: -0.16%
H: 0.49%
C: -0.27%
welireg fda drug renal review cell application
European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
Published: 2023-09-07 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: 0.39%
H: 1.66%
C: 0.96%
LUMO | $2.855 1.96% 45K
|
Health Technology
|
| O: 0.3%
H: 5.6%
C: -0.74%
ervebo children year
Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Published: 2023-09-05 (Crawled : 12:00) - biospace.com/
MS | News 0 d | $93.88 0.13% 2.7M
|
Finance
|
| O: 0.01%
H: 0.0%
C: 0.0%
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: -0.35%
H: 0.24%
C: -1.78%
conference merck global
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Published: 2023-08-25 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: 0.45%
H: 0.35%
C: 0.25%
mk-0616 candidate merck program
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Published: 2023-08-25 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: 0.45%
H: 0.35%
C: 0.25%
leap-010 keytruda merck update cell trial plus
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-24 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
|
| O: 1.28%
H: 0.0%
C: 0.0%
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: -0.31%
H: 0.96%
C: -1.35%
lynparza japan approved cancer treatment plus
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Published: 2023-08-18 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: 0.05%
H: 0.49%
C: 0.21%
spark-005 welireg renal merck cell trial
U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
Published: 2023-08-03 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: -0.59%
H: 0.67%
C: 0.62%
LUMO | $2.855 1.96% 45K
|
Health Technology
|
| O: 3.05%
H: 0.0%
C: -5.62%
ervebo fda children
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
Published: 2023-07-28 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: 0.15%
H: 1.16%
C: 0.86%
ynote-756 breast merck cancer trial response
Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1
Published: 2023-06-29 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: -0.17%
H: 1.45%
C: 1.15%
sales conference merck
Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Published: 2023-06-20 (Crawled : 12:00) - biospace.com/
MRK | $127.345 0.37% 4.6M
|
Health Technology
|
| O: -0.22%
H: 1.63%
C: 1.05%
ynote-585 merck update trial
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3831 151.54% 190M
|
Consumer Services
CZOO | $11.04 121.24% 11M
|
LICN | $0.9107 62.63% 14M
|
BOF | $1.87 59.83% 100M
|
AMST | $3.18 59.0% 67M
|
Technology Services
MTC | $3.31 47.77% 7.7M
|
Technology Services
MULN | News | $3.915 43.41% 12M
|
Information
WIMI | $1.04 43.37% 17M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
RILY | $30.01 38.17% 11M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.